There are 2934 resources available
What benefit can we expect from emerging targeted agents including ICI to improve survival?
Presenter: Margaret Tempero
Session: ESMO Colloquium supported by Celgene - Pancreatic cancer: Can better understanding of biology improve resectability and survival?
Resources:
Slides
How far would you go in your treatment?
Presenter: Anna Sophie Berghoff
Session: The Hans Keulen Memorial Debate
Resources:
Slides
Webcast
2274 - ACHIEVE-2 trial: a randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)
Presenter: Takayuki Yoshino
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Abstract
Slides
Webcast
6254 - Results of the TAPPAS trial: An adaptive enrichment Phase 3 trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)
Presenter: Robin Lewis Jones
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
3086 - CRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumor (DT) patients (pts)
Presenter: Jean-Emmanuel Kurtz
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
5459 - IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- Soft-tissue sarcoma cohort
Presenter: Javier Martin Broto
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
5471 - ADP-A2M4 (MAGE-A4) in patients with Synovial Sarcoma
Presenter: Brian Van Tine
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
6136 - Clinical Outcomes by Chemotherapy Regimen in Patients with RS 26-100 in TAILORx
Presenter: Joseph Sparano
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
4667 - Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
Presenter: Michael Untch
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
4794 - INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ripretinib as _4th-Line Therapy In Patients With AdvanCed Gastrointestinal Stromal TUmorS (GIST) Who have Received Treatment With Prior Anticancer Therapies (NCT03353753)
Presenter: Margaret von Mehren
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast